Hypertension:难治性高血压真的难治吗?

2013-12-16 晓静 编译 医学论坛网

英国一项研究表明,虽然难治性高血压在高血压患者中相对常见,但真正抗高血压治疗失败是罕见的。相关论文12月9日在线发表于《高血压》(HYPERTENSION)杂志。 研究纳入REGARDS 研究中的14 809例基于人群队列的接受抗高血压治疗的受试者,评估其难治性高血压发病率和相关心血管危险因素以及并存疾病。以≥5种不同级别的抗高血压药难以控制的血压(收缩压/舒张压≥1

英国一项研究表明,虽然难治性高血压高血压患者中相对常见,但真正抗高血压治疗失败是罕见的。相关论文12月9日在线发表于《高血压》(HYPERTENSION)杂志。

研究纳入REGARDS 研究中的14 809例基于人群队列的接受抗高血压治疗的受试者,评估其难治性高血压发病率和相关心血管危险因素以及并存疾病。以≥5种不同级别的抗高血压药难以控制的血压(收缩压/舒张压≥140/90 mm Hg)定义为难治性高血压。将用≥3种不同级别药物控制收缩压/舒张压≥140/90 mm Hg或用≥4种不同级别药物控制收缩压/舒张压<140/90 mm Hg的顽固性高血压患者以及所有接受高血压治疗的受试者作为对照组。

结果显示,受试者中有78 例(0.5%)为难治性高血压。在顽固性高血压患者中(n=2144),难治性高血压的患病率为3.6%,这一发病率在应用≥5种不同级别抗高血压药物的患者中为41.7%。在所有受试者中,合并高血压、黑色人种、男性、居住于卒中高发带、较高的体质指数、心率较低、肾小球滤过率减少、蛋白尿、糖尿病、卒中史和冠心病史与难治性高血压相关。

与顽固性高血压相比,黑色人种和合并蛋白尿以及合并糖尿病的患者难治性高血压患病率增加。与对照组患者相比,冠心病和卒中的中位10年Framingham危险评分在难治性高血压患者中较高。

原文出处:

Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P.Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort.Hypertension. 2013 Dec 9. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038477, encodeId=713420384e7fb, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 04 16:55:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725557, encodeId=e14d1e25557e9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 14 04:55:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501031, encodeId=40121501031f1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528259, encodeId=3071152825919, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038477, encodeId=713420384e7fb, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 04 16:55:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725557, encodeId=e14d1e25557e9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 14 04:55:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501031, encodeId=40121501031f1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528259, encodeId=3071152825919, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=)]
    2014-09-14 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038477, encodeId=713420384e7fb, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 04 16:55:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725557, encodeId=e14d1e25557e9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 14 04:55:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501031, encodeId=40121501031f1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528259, encodeId=3071152825919, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038477, encodeId=713420384e7fb, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 04 16:55:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725557, encodeId=e14d1e25557e9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 14 04:55:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501031, encodeId=40121501031f1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528259, encodeId=3071152825919, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Dec 18 05:55:00 CST 2013, time=2013-12-18, status=1, ipAttribution=)]
    2013-12-18 freve

相关资讯

JACC:去肾神经术治疗难治性高血压患者

  目的  本研究旨在评价去肾神经术(RDN)治疗难治性高血压患者的成本效益和长期临床益处。   背景  难治性高血压累及12%的高血压患者。Symplicity HTN-2随机对照试验显示,RDN可使收缩压从基线时的(178 ± 18)mm Hg降低(32 ± 23)mm Hg。   方法  采用状态转换模型预测RDN和标准治疗对10年及终生卒中、心肌梗死、所有

2012EASO-ESH+联合声明-肥胖和难治性动脉高血压:控制体重的降压获益是否被高估了?

       近期,欧洲肥胖症研究学会(EASO)和欧洲高血压学会(ESH)共同发表了肥胖和难治性动脉高血压联合声明,声明中指出,肥胖症患者易于罹患高血压,常需要更多降压药物治疗,此类患者难治性高血压风险增加。        肥胖和高血压常并存于同一患者,二者间的关联可能因遗传机制等表现出较大的个体差异。肥胖影响

J Hypertens:HOT-CHINA研究发现中国难治性高血压发生率较低

研究要点: 中国高血压最佳治疗研究(2001.4-2002.2)在大陆148个城市中招募54590名成年高血压患者,并应用五步治疗法治疗患者。 研究结果发现,中国难治性高血压与超重/肥胖、较高血压和代谢综合征相关。而中国难治性高血压的发生率仅为1.9%。 研究结果发表于《高血压杂志》。 本项研究根据中国高血压最佳治疗试验(Hypertension Optim

难治性高血压诊断治疗中国专家共识

  由北京大学人民医院孙宁玲教授、北京大学第一医院霍勇教授、上海市高血压研究所王继光教授等国内知名专家制定的《难治性高血压诊断治疗中国专家共识》(以下简称共识)近日发表于2013年第4期《中华高血压杂志》上。   共识指出难治性高血压(RH)的定义为,在改善生活方式的基础上,应用了合理可耐受的足量≥3种降压药物(包括利尿剂)治疗>1月血压仍未达标,或服用≥4种降压药物血压才能有效控制。目前RH患

EHJ:ESC支持肾脏去神经化能用于难治性高血压治疗

     日前,欧洲心脏病学会(ESC)发布了一份共识声明,称经导管肾脏去交感神经术(catheter-based renal denervation),也称经导管肾交感神经消融术,可作为高血压治疗的一种备选治疗策略,适用于在生活方式调整和药物治疗后未达到降压目标的耐药性高血压患者。     本声明在线发表于2013

压力反射刺激疗法(BAT)治疗顽固性高血压的新进展

  最近,来自第三军医大学大坪医院心血管病医院、重庆市心血管病研究所的曾春雨在第二届中国高血压大会暨中国医师协会高血压专业委员会年会上报告了压力反射刺激疗法(BAT)治疗顽固性高血压的新进展。   BAT降压机制   刺激颈动脉压力感受器,影响大脑自主神经系统,从而抑制交感神经活性,增强副交感神经活性,最终使心率下降,血管舒张、僵硬度下降,尿钠排出增加,肾素分泌减少。